Novo Nordisk (NVO 1.41%) hopes to be the first to market with an oral version of its weight loss treatment.
*Stock prices used were the afternoon prices of Nov. 18, 2025. The video was published on Nov. 20, 2025.

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.
Novo Nordisk (NVO 1.41%) hopes to be the first to market with an oral version of its weight loss treatment.
*Stock prices used were the afternoon prices of Nov. 18, 2025. The video was published on Nov. 20, 2025.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.